Abbott seeks appeal on royalties to UK's Cambridge
Tuesday, 15 February, 2005
Abbott Laboratories is seeking to appeal a British court ruling that granted Cambridge Antibody Technology a greater percentage of royalties on Abbott's arthritis drug Humira.
In December, UK Judge Hugh Laddie said Abbott should pay Cambridge a royalty of just over 5 per cent on sales of Humira, compared with the royalty of 2 per cent of net sales it has been paying.
The application will be considered by one Court of Appeal judge, Cambridge said in a statement. If the application is unsuccessful, Abbott will be entitled to request a hearing.
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
